Group 1 - The core viewpoint of the news is that 巨子生物 (Giant Bio) reported its mid-year results for 2025, showing a revenue of approximately 3.113 billion yuan, a year-on-year increase of 22.5% [1] - The gross profit for the company was about 2.542 billion yuan, reflecting a year-on-year growth of 21.5% [1] - The net profit attributable to the parent company was around 1.182 billion yuan, which represents a year-on-year increase of 20.2% [1] Group 2 - The 可复美 (Kefumei) brand generated revenue of 2.54 billion yuan, marking a year-on-year growth of 22.7% [1] - The 可丽金 (Kelin) brand achieved revenue of 500 million yuan, with a year-on-year increase of 26.9% [1] - In the same period last year, the company's revenue and net profit attributable to the parent company had year-on-year growth rates of 58.2% and 47.4%, respectively [1] Group 3 - Following the 可复美 5.24 incident, the brand experienced some impact, but the overall situation is considered manageable [2] - During the 618 shopping festival, 可复美 ranked 16th on Tmall, compared to 12th in 2024 [2] - Sales data showed a rebound in July, with 可复美's Tmall and Douyin GMV increasing by 70% and 17% year-on-year, respectively [2]